Hypoxia and Heart Rate Variability
Part of paid clinical trials in Miami, Florida.
- Sponsor
- University of Miami
- Study ID
- NCT05606406
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Accepted
Interventions
- Nocturnal Oxygen — OTHERNocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
Study Details
The purpose of this study is to evaluate how variations in oxygen demands may change heart electrical activity in individuals with and without oxygen dependence.
Key Dates
- Start date
- May 30, 2026
- Status verified
- Feb 2026
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2027
Study Design
- Enrollment
- 70 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Healthy Control GroupIndividuals without lung disease will receive oxygen for a period of four hours
- Active Comparator: Nocturnal hypoxemia groupIndividuals with lung disease will receive oxygen for a period of four hours
Primary Outcome Measure
QT Variability Index [ Time Frame: Up to 10 hours ]
Central Contacts
- Trishul Siddharthan, MD305-243-6388
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Miami | Miami | Florida | 33136 | Trishul Siddharthan, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Miami, FL
By condition
By specialty
By research site
Related Studies
- A Study of the Effect of a Nurse Navigator Program on High Risk PatientsNot Yet Recruiting · Mayo Clinic · Jacksonville, Florida
- Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)PHASE3 · Recruiting · GlaxoSmithKline · Loxahatchee Groves, Florida
- Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)PHASE3 · Recruiting · GlaxoSmithKline · Sheffield, Alabama
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPHASE3 · Recruiting · GlaxoSmithKline · Doral, Florida